Oncology Q&A: Addressing Common Questions Posed by Patients with Metastatic Triple-Negative Breast Cancer | Research To Practice

LIVE WEBINAR: Tuesday, January 7, 2025, 5:00 PM – 6:00 PM ET Register for this complimentary event with the “Register Now” button above, which will take you to our Zoom registration page. Join us on Tuesday, January 7 th for this CME/MOC-accredited webinar 5:00 PM – 6:00 PM ET Faculty Lisa A Carey, MD, ScM, FASCO L Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research Deputy Director for Clinical Sciences Lineberger Comprehensive Cancer Center University of North

Read the full article here

Source: www.researchtopractice.com

Categories: Hem/Oncs, General Medicine News

Tweets with this article

Research To Practice

Next month, in collaboration with the @TNBCFoundation - Dr Neil Love will explore common questions posed by patients with metastatic triple negative breast-cancer. Register at the link below: https://t.co/IhccH6MFtw https://t.co/2RoQdQUFjC

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials – PubMed

SABR shows excellent long-term disease control for low- and intermediate-risk localized prostate cancer. Patients treated for prostate cancer have a moderate risk of SM, consistent…

Dr. Andrew Loblaw January 7, 2025

Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma—Less Is More

Current up-front therapeutic approaches for classic Hodgkin lymphoma (cHL) in children and young adults aim to reduce treatment intensity to minimize long-term treatment-related morbidity. This…

Rabi Hanna January 7, 2025

Understaffed GP practices ‘not ready’ to take on more work from hospitals

Most GPs say their practice doesn’t have the staff to cope with government plans to shift more healthcare into the community, according to polling by…

Ash Paul January 7, 2025

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib

Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment…

Joshua Bauml, MD January 7, 2025

Virtual Meetings | Research To Practice

Research To Practice (RTP) is pleased to offer these complimentary 1-hour CME/MOC-accredited virtual sessions. Each session will be moderated by Dr Neil Love and feature…

Research To Practice January 7, 2025

ESTRO/EANO recommendation on reirradiation of glioblastoma

Reirradiation of brain tumors has a long history of preclinical and clinical studies especially with regards to effectiveness and safety in the recurrent setting. Clinical…

Gil Morgan January 7, 2025

How can task shifting put patient safety at risk? A qualitative study of experiences among general practitioners in Norway

Objective: To describe experiences among general practitioners (GPs) in Norway regarding horizontal task shifting experiences associated with adverse events that potentially put patient safety at…

Ash Paul January 7, 2025

Coughing won’t save you if you’re having a heart attack, despite what people claim on social media

‘Cough CPR’ is blowing up on social media. But it’s not to be recommended.

Ash Paul January 7, 2025

Andexanet alfa: trials just leave us with more questions

ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with…

Michael Makris January 7, 2025

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

PURPOSEDatopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2–directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier:…

Stephen V Liu January 7, 2025

Related Articles